Category Archives: Healthcare Solutions

Healthcare, Healthcare Products, Healthcare Solutions, Homeopathic Treatment

Global Kidney Stone Management Device Market: Higher end user preference for lithotripsy devices, particularly extracorporeal variants prevails

Leave a comment

DUBLIN 2, Ireland, 30-Oct-2018 — /EPR HEALTHCARE NEWS/ — Fact.MR has recently announced the launch of a new research study that delivers key market insights on kidney stone management management devices. The comprehensive report on kidney stone management devices market offers actionable intelligence, offering volume and value projections for a 10 year timeline (2018-2028).

Free sample of the kidney stone management devices market report is available on the below link.

https://www.factmr.com/connectus/sample?flag=S&rep_id=1827

Key Insights from Report:

  • United States remains the largest market for kidney stone management devices, accounting for over 88 percent of global sales in 2017
  • Eastern Europe and United Kingdom led demand for kidney stone management devices in Europe during 2018 and the trend is likely to continue in the future as well
  • Sales are encouraging in EU-4; growth is relatively slower than UK and Eastern European countries. EU-4 is likely to create significant opportunities for market players
  • Hospitals are the key sales channel, accounting for nearly 50% of total sales in 2017
  • Higher end user preference for lithotripsy devices, particularly extracorporeal variants prevails – lithotripsy devices will remain the top-selling segment in 2019 and beyond

Lithotripsy Devices Lead the Rally

Fact.MR reveals that sales of extracorporeal lithotripsy devices accounted for over 73 percent of the lithotripsy sales and over 60 percent of overall kidney stone management device sales in 2017, surpassing those generated from ureteroscopes and nephroscopes.

The demand for lithotripsy devices across developed countries of the United States and the EU-4 is projected to expand at a significant pace in the coming years. Sales of kidney stone management devices in United States alone are likely to cross US$ 200 Mn by end of 2018-end, maintaining the status quo of the country as the most attractive market.

The US remains a lucrative market for stakeholders, reflecting a 1.5x lead in sales over EU-4 combined and a 1.2x lead over China, India and ASEAN in 2018.

Kidney Stone Management Devices Sales
Country 2013 2015 2017 2018 2020 2025 2028
US XX XX XX XX XX XX XX
EU-4 XX XX XX 133.2 XX XX XX
China, India and ASEAN XX XX XX XX XX XX XX

(Note: All above figures are in US$ Mn)

Speak to the authors of the report for additional information on the redacted figures  

Medical Tourism Hubs in Asia: The New Growth Frontiers

Kidney stone management devices are likely to witness increasing traction among emerging economies in the Asia Pacific, such as China and India, albeit at a lower base. China remains lucrative, maintaining a 1.5X lead over India in 2018. India and ASEAN currently account for less than 10% share of the global market; however, opportunities abound as these countries position themselves as global medical tourism hubs.

For direct purchase of the kidney stone management devices market report, please click on the link below:

https://www.factmr.com/checkout/1827/S

SOURCE: EuropaWire

Business of Medicine, Healthcare, Healthcare Information, Healthcare Products, Healthcare Services, Healthcare Software, Healthcare Solutions

IBM Watson Market Study: IBM Watson services have been positively disrupting and reforming operations in the healthcare industry

Leave a comment

DUBLIN 2, Ireland, 10-Oct-2018 — /EPR HEALTHCARE NEWS/ — IBM Watson Services continue to get significant traction from end-users, with over 72% respondents in Europe affirmative on using IBM Watson language services, according to a Fact.MR survey. The survey is part of the comprehensive research study on IBM Watson services market which tracks the adoption of this platform across key sectors. The Fact.MR survey also reveals that use of IBM Watson vision services attracted the minimum interest, with only 48% of respondents in Europe affirmative about using it.

Fact.MR’s IBM Watson services market survey gathered data from over 500 respondents in 10 European countries. These respondents represented large-scale, SMEs, and micro organizations, with a collective IT spending budget of over US$ 50 billion. The findings of the survey were in sync with the overall expectations and use of IBM Watson services, which are highly reliant on revenue generated from language services.

Growing Realization that Cognitive Technologies Can Empower Decision-Making 

The survey indicates that mitigating the gaps that exist in IT vendors’ execution from data collection to action remains the key concern of organizations. There is an increasing realization among IT vendors that cognitive technologies can empower decision-makers to make sense of colossal structured and unstructured data. The survey offers encouraging insights on the growing use of advanced analytics and cognitive computing in today’s data-driven economy, as over half of the respondents in the survey agreed to using insights- and speech-services of IBM Watson.

Request Sample of IBM Watson Services Market Report at https://www.factmr.com/connectus/sample?flag=S&rep_id=759

“Today, the requirements of organizations are multi-pronged – from gaining a holistic customer view to agile data-to-execution operations, organizations need to invest in cognitive computing and advanced technologies to stay competitive,” says Shambhu Nath Jha, Senior Consultant at Fact.MR and co-author of the study.

“IBM Watson services have been positively disrupting and reforming operations across sectors, especially healthcare. From screening patient’s structured and unstructured data to regulatory requirements and medications, IBM Watson services are witnessing extensive adoption in the healthcare sector,” added Mr. Jha. The growing adoption of IBM Watson services in healthcare is further substantiated by Fact.MR’s findings that the sector currently accounts for nearly 21% revenue share, representing a market value worth US$ 318 Mn.

Improved Business Agility and Seamless Customer Service Identified as Key Advantages 

The Fact.MR survey further reveals that improvement in business agility is the most prominent motivation driving investment in IBM Watson services. Nearly 84% of respondents currently using IBM Watson services said that there was a marked improvement in business agility since the introduction of platform in their organization. An additional 82% said IBM Watson services helped their organizations in improving and transforming customer service.

“Customer service has often remained a key concern for organizations; despite the proliferation of advanced technologies and pervasiveness of smartphones, nearly 50% of customer support calls remain unresolved,” says Shambu Nath Jha. “The integration of artificial intelligence (AI) can mitigate this challenge, and offer seamless support for Tier 1 queries. The system can also effectively gauge the queries that require human intervention, and escalate those queries to a customer support executive if necessary,” adds Mr. Jha.

Know the methodology behind the report 

https://www.factmr.com/connectus/sample?flag=RM&rep_id=759

Effective decision-making, handling colossal structured and unstructured data, and sales assistance are among the other key advantages of using IBM Watson services, according to the Fact.MR survey. “Effective decision-making entails a deep understanding of the unique needs and requirements of customers. Today, businesses are hard-pressed to understand the unique characteristics of their customers, and effectively map their existing and upcoming products to meet the overt and covert needs. IBM Watson can provide sophisticated recommendations that can facilitate effective decision-making,” Mr. Jha added.

Fact.MR’s report on the global IBM Watson services market projects a surge in investments to mitigate cybersecurity risks. According to Fact.MR, a majority of organizations have some level of cybersecurity apparatus in place. However, as Mr. Jha concludes, “tackling the potent cybersecurity threats will require a comprehensive ecosystem, rather than a symbolic front-line defense.”

The IBM Watson Services Market Report is Available for Direct Purchase at

https://www.factmr.com/checkout/759/S

SOURCE: EuropaWire

Alternative medicine, Disorders, Healthcare, Healthcare Products, Healthcare Services, Healthcare Solutions, Non-Surgical Procedure, Therapies, Urology

Study published in World Journal of Urology confirms Fotona SMOOTH® laser technology is a safe, effective & minimally-invasive solution for stress and mixed urinary incontinence

Leave a comment

LJUBLJANA, Slovenia, 21-Sep-2018 — /EPR HEALTHCARE NEWS/ — The latest study published in the World Journal of Urology (Comparison between erbium‑doped yttrium aluminum garnet laser therapy and sling procedures in the treatment of stress and mixed urinary incontinence – https://doi.org/10.1007/s00345-018-2445-x) provides further confirmation that Fotona SMOOTH® laser technology is a safe, effective and minimally-invasive solution for stress and mixed urinary incontinence (SUI and MUI). The article, written by Dr. Nobuo Okui, compares Fotona’s minimally invasive IncontiLase® Er:YAG laser therapy with the more conventional TVT and TOT surgical sling procedures.

Asian Study Confirms Favorable Results of Fotona SMOOTH® Laser Therapy for Urinary Incontinence

In the study performed by Dr. Okui, 50 Japanese women were treated either surgically (tension-free vaginal tape – TVT or transobturator tape – TOT) or with a Fotona laser. The 1-h pad test, ICIQ-SF, and overactive bladder-symptom score were used to assess the patients before and 12 months after treatment. Laser therapy was performed by first applying a local anesthetic to the vaginal wall and then inserting a probe into the vagina. Laser irradiation was performed for 20 min with an Er:YAG wavelength of 2940 nm (Dynamis XS, Fotona) for a total of three treatments (alternating every month). Results of the 1-h pad test and ICIQ-SF showed comparable improvements in SUI in the sling and laser therapy groups, while some of the patients with MUI in the TVT and TOT groups showed exacerbation. In conclusion, the TVT and TOT procedures and the laser therapy are comparable for SUI; however, laser therapy is superior in terms of MUI and complications. The study thus once again confirms the safety and efficacy of Fotona SMOOTH® laser therapy for urinary incontinence.

Urinary Incontinence Treatment Options

Conventional treatment options for urinary incontinence are surgical, and include TVT or TOT sling procedures, which involve inserting a synthetic material. Problems often arise with artificial meshes that require new treatment methods. With the Fotona SMOOTH® Er:YAG laser thermotherapy (also known as IncontiLase®), the goal is to provide a minimally invasive therapy based on vaginal collagen hyperthermia followed by collagen remodeling and new collagen synthesis, which results in overall regeneration of aged or stressed vaginal tissues and subsequently greater support to the bladder.

Unique Fotona SMOOTH® Technology for Maximum Safety

Patient safety is the primary concern and, for this reason, the patented Fotona SMOOTH® technology holds a very unique position within the spectrum of gynecological treatment options. It is a non-surgical procedure (no incisions) and without implants or appliances. The Fotona SMOOTH® method of dual-tissue regeneration is completely non-ablative and therefore minimally invasive to the vaginal wall. The treatment involves an additional superficial heat-shocking mechanism of tissue regeneration, and a unique self-regulating safety feature. These dual-tissue regeneration characteristics of the Fotona SMOOTH® Er:YAG laser allow for an exceptionally high degree of safety and efficacy in thermotherapy of the vaginal wall. This is what makes Fotona SMOOTH® a significantly safer alternative to many widely used and more-invasive procedures.

Evidence-Based Laser Medicine

Over the past few years numerous (over 35) other studies on Fotona SMOOTH® laser therapy have been published by distinguished gynecologists from around the globe in some of the most trusted and renowned international scientific journals, all with favorable results (https://www.laserandhealthacademy.com/en/practitioners/recommended-reading/gynecology/). One such noteworthy clinical paper published in March 2018 by Dr. Adolf Lukanovic and Dr. Mija Blaganje is the first randomized controlled trial study (on 114 premenopausal parous women) to evaluate the efficacy and safety of non-ablative Er:YAG laser therapy as an alternative non-invasive treatment of SUI and the improvement of sexual gratification (published in the European Journal of Obstetrics & Gynecology and Reproductive Biology. 2018 (224): 153-158). The results from this study indicate that a single session of IncontiLase® treatment improves the impact of SUI symptoms on quality of life and sexual function in premenopausal parous women significantly better than placebo.

In another Asian study, Dr. Yi-Wen Tien et al. from the Chang-Hua Hospital in Taiwan examined the effects of laser treatment for female SUI on pad weight, urodynamics, and sexual function in 35 women (published in the International Urogynecology Journal. 2017; 28(3): 469-476). The study reveals that the effect of IncontiLase® treatment for mild SUI was moderate at the 6-month follow-up. Moreover, it improved LUTS, quality of life, and the sexual function of both partners. The authors conclude that the IntimaLase® procedure is very effective in the treatment of SUI and is not associated with any severe adverse effects.

Similarly, Dr. Yi-Hao Lin et al. from the Chang Gung Memorial Hospital in Taiwan obtained favorable results. Their study investigated the effects of non-ablative laser treatment on overactive bladder (OAB) syndromes, SUI and sexual function in 30 women with urodynamic stress incontinence (published in the Taiwanese Journal of Obstetrics & Gynecology. 2017 (56): 815-820). The results showed that IncontiLase® treatment can resolve SUI and coexistent OAB symptoms three months after therapy, while repeated laser therapy may be necessary after six months. The results also revealed that sexual gratification improved, while no major adverse effects were noticed.

The quantity and quality of the studies performed with Fotona SMOOTH® laser therapy is such that Fotona’s Dynamis has been cleared in the European Union for SUI (IncontiLase®), vaginal laxity – vaginal relaxation syndrome (IntimaLase®), genitourinary syndrome of menopause – GSM (RenovaLase®) and pelvic organ prolapse (ProlapLase®), giving women the option to choose a safer and less-invasive treatment alternative. In Asia, the Taiwan Food and Drug Administration has already cleared Fotona Dynamis for mild to moderate SUI, and the Singapore Health Sciences Authority has cleared the Dynamis for the treatment of SUI and GSM.

SOURCE: EuropaWire

Alternative medicine, Biotech, Drugs, Healthcare, Healthcare Products, Healthcare Professionals, Healthcare Services, Healthcare Solutions, Homeopathic Treatment, Medicine, Pharmaceuticals, Public Health, Therapies

Dr. Christina Marrongelli chosen by the World Congress on Pharmacology & Chemistry of Natural Compounds to moderate their 2018 conference in Paris

Leave a comment
Dr. Christina Marrongelli chosen by the World Congress on Pharmacology & Chemistry of Natural Compounds to moderate their 2018 conference in Paris

Marrongelli selected for her expertise in Botanical Drug Development

LONDON, Jun-16-2018 — /EPR Healthcare News/ — As a leading expert in her field, Dr. Christina Marrongelli, PharmD has been chosen by the World Congress on Pharmacology & Chemistry of Natural Compounds to moderate their 2018 conference: Exploring New Trends & Innovations in Pharmacology and Natural Compounds. The conference is being held in Paris, France on June 18, 2018.

Dr. Marrongelli, who is an adjunct professor at the Medical University of South Carolina in the department of drug discovery and biomedical sciences will also present “Developing and Marketing Botanical Drugs in the United States”.

The United States, which has the largest pharmaceutical market in the world, demonstrates a strong demand for the use of botanicals as medicine. However, to date only two prescription botanical drugs are currently approved for use in the USA: Veregen® (sinecatechins) and Mytesi™Â (crofelemer).

Marrongelli attributes this disconnect between supply and demand to hidden barriers. She notes that with the worldwide herbal drug market is expected to reach nearly $86.74 billion by 2022, businesses must identify and address these barriers so that heterogeneous botanical drug products can obtain the approvals necessary to meet the consumers growing expectations and demands for botanical medicines.

To further explain the barriers to regulation of botanicals, Marrongelli points to the Botanical Drug Development Guidance for Industry from the U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER) that was last updated in 2016. According to publication, regulation of botanicals in the U.S. is different from regulation in the rest of world. The U.S. does not have a separate regulatory category for traditional or herbal medicines: A botanical product may be classified as a food (including a dietary supplement), drug (including a biological drug), medical device, or cosmetic under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Whether an article is a food, drug, medical device, or cosmetic depends in large part on its intended use.

To learn more about the issues and barriers to the development of botanical drugs, please contact Dr. Marrongelli at Marronge@musc.edu or DrM@pharmD.expert.

SOURCE: EuropaWire

Biotech, Geriatrics, Healthcare, Healthcare Products, Healthcare Services, Healthcare Software, Healthcare Solutions, Public Health, Society, Telemedicine

Health Innovation Centre of Southern Denmark, Fraunhofer Institute Portugal and ProjectRay named the winners of the European Silver Economy Awards 2018

Leave a comment
Winners of the first European Silver Economy Awards: Boaz Zilberman (ProjectRay), Anne Friis Hansen (Health Innovation Centre of Southern Denmark) and Ana Vasconcelos (Fraunhoder Institute Portugal)

BRUSSELS, Belgium, 20-May-2018 — /EPR Healthcare News/ — On Thursday May 3, the first edition of the European Silver Economy Awards has celebrated its winners under the patronage of Mariya Gabriel, Commissioner for Digital Economy and Society, and Markku Markkula, First Vice-President of the Committee of the Regions. The ceremony took place at the Committee of the Regions in Brussels and has been designed as an event that brings together key speakers and innovators from both the public and private sector.

The first prize in the category Public Authorities has been awarded to the Health Innovation Centre of Southern Denmark (Denmark) for their Generic Telemedicine Platform. The Fraunhofer Institute Portugal (Portugal) submitted a tool for fall prevention and detection (GoLive Solutions) and was the winning Non-for Profit Organisation. Introducing a smartphone solution (RAY Solutions) for visually impaired people, ProjectRay (Israel) has won in the category For Profit Organisation.

The Silver Economy Awards have been launched to recognise and reward innovative ICT solutions from all sectors, to raise awareness of the potentials of this section of the economy and to bring together European stakeholders under a common goal: supporting and improving the quality of life of older persons in society. On behalf of Commissioner Gabriel, Cabinet Member Manuel Mateo Goyet described the first Silver Economy Awards as representing a “milestone on our way towards becoming a truly age-friendly Europe”, and promoted the ceremony as “a unique occasion to send a very positive message on how we see the future of ageing” showing “the true value of collaboration in Europe”.

Celebrating the nine finalists and their dedication to making Europe an age-friendlier place, Markku Markkula, host and moral patron of the Silver Economy Awards, declares his acknowledgement: “I want them in my region”. More than 95 applications coming from 22 countries have been submitted for consideration in three awards categories referring to the type of organisation. Over 40 Silver Economy experts were involved in the three-staged evaluation process to determine Winner, Second and Third.

For more details on the winner entries and an overview of the final ranking of the first European Silver Economy Awards 2018 edition please visit www.silvereconomyawards.eu/sea/2017/awards#Winners.

SOURCE: EuropaWire

Biotech, Business of Medicine, Diseases, Drugs, Health 2.0, Healthcare, Healthcare Professionals, Healthcare Services, Healthcare Software, Healthcare Solutions, Medicine

Alliance Life Sciences to present expanded portfolio of pricing & market access services at the World Pharma Pricing and Market Access Congress 2018

Leave a comment

SOMERSET, N.J. / LONDON, UK, 19-Mar-2018 — /EuropaWire/ — Alliance Life Sciences, a leading global life sciences consulting, pricing data and technology provider, announced that it is a sponsor at the World Pharma Pricing and Market Access Congress 2018 taking place March 20-21 in London, United Kingdom. As part of the largest pharmaceutical commercialization organization that services more than 300 of the industry’s top pharmaceutical, biotech and medical device companies, Alliance will present its expanded portfolio of pricing and market access services. The focus will be on pricing and reimbursement data managed by PricentricOne and pricing governance, reference and tender pricing software manage by PriceRight.

Now in its 12th year the World Pharma Pricing and Market Access Congress brings together the most innovative leaders and organizations to discuss all aspects of evidence, access and pricing. This year’s event will feature over 150 speakers and a greater range of topics being covered including Big Data & AI, rare diseases, advanced therapies and other emerging, innovative areas.

Alan Crowther, President of Global Markets noted “Alliance Life Sciences is pleased to be a sponsor of the World Pharma Pricing & Market Access congress, particularly this year. We have made a number of investments in our people and infrastructure in Europe. Our acquisition by Water Street partners in 2017 allowed us to offer enhancements in our Market Access offerings too. Europe continues to be our focus market and World Pharma Pricing & Market Access congress is a great venue to showcase our expended capabilities”.

SOURCE: EuropaWire

Business of Medicine, Cancer, Diagnostics, Diseases, Health 2.0, Healthcare, Healthcare Products, Healthcare Professionals, Healthcare Services, Healthcare Software, Healthcare Solutions, Non-Surgical Procedure, Oncology, Therapies

Multispectral Optoacoustic Tomography (MSOT) can now more reliably detect early stages of inflammation

Leave a comment

GERMANY, Mar-30-2017 — /EPR HEALTHCARE NEWS/ — Ulcerative colitis and Crohn’s disease are the most common inflammatory bowel diseases (IBD). Globally, more than 4 million people suffer from recurring inflammation of the intestinal mucosa. To date, non-invasive methods have not been able to detect these forms of IBD reliably. Researchers at the University Hospital Erlangen (Germany) have now shown for the first time how Multispectral Optoacoustic Tomography (MSOT) can more reliably detect early stages of inflammation when compared with other non-invasive diagnostic methods. These results have recently been published in the New England Journal of Medicine.

Evaluating the inflammatory activity of the intestines early and accurately helps to prevent complications associated with IBD and guide an optimal therapy regime. Currently, doctors frequently rely on an invasive endoscopy procedure to assess the intestinal mucosa of patients with IBD. Additionally, non-invasive imaging methods are increasingly used in the clinic. For example, ultrasound allows clinicians to examine the structure, thickness and blood perfusion of the intestinal wall with changes in perfusion patterns indicating an onset of inflammation.

“With the MSOT procedure, we additionally use laser light, by which we can detect inflammation earlier than previously possible with ultrasound”, explains Prof. Dr. Maximilian Waldner, Professor at the University Hospital Erlangen. “The earlier we detect signs of an upcoming flare – i.e., a change in blood content – the quicker we can react and start a preventive treatment”. The MSOT technology was developed by iThera Medical in Munich, and was first used on IBD patients last year.

The researchers of the University Hospital Erlangen have recently published their results in the renowned New England Journal of Medicine. “We examined 108 patients with Crohn’s disease using the MSOT technology and compared the results to established non-invasive diagnostic procedures as well as endoscopy and histology”, says Prof. Waldner. “We were able to demonstrate that hemoglobin values in the tissue measured with MSOT indicate very accurately the inflammatory activity in the intestines. The method appears to be superior to other non-invasive procedures, as MSOT for the first time was able to detect even low levels of inflammation without having to perform endoscopy”.

Dr. Ferdinand Knieling, a physician at the University Hospital Erlangen, adds: “We are hoping that this principle can be applied to many applications and, in particular, also be used to enable safe evaluations of children and adolescents. With this new examination method, many of the currently invasive procedures might become obsolete.”

In optoacoustic imaging, the physician scans the intestines transabdominally through the skin, applying pulsed laser light in the near-infrared region. The energy of the light absorbed in tissue is converted into acoustic signals which are then acquired by an ultrasound detector. Christian Wiest, CEO of iThera Medical, comments: “MSOT is a new diagnostic imaging modality that can detect changes in tissue composition associated with a variety of diseases, without the use of contrast agents. The technology has already been applied in other clinical feasibility studies, e.g. for the detection of melanoma metastasis in sentinel lymph nodes or for the assessment of suspicious breast lesions”.

The results of the IBD study at the University Hospital Erlangen were published on March 30th 2017 in the New England Journal of Medicine (Volume 376, Issue 13, pg.1292-1294).

SOURCE: EuropaWire

Healthcare, Healthcare Products, Healthcare Software, Healthcare Solutions, Society

Startup mentored by Promwad created one of the best IoT products in Europe

Leave a comment

Vilnius/Lithuania, 2016-Oct-18 — /EPR Healthcare News/ — ZIVE smart radiation monitor has reached the final of Elektra Awards 2016, a big influential contest for the electronics market players. This device designed by R-NOX startup with the assistance of Promwad Electronics Design House was named one of six best innovative products of Europe exploiting the Internet of Things potentialities.

ZIVE is a portable radiation monitor of the next generation that can connect to smartphones and tablets via Bluetooth. It’s the first device of professional level designed for common people. It has a user-friendly interface, a Geiger-Muller counter, and a low market price comparing with other high-precision radiation monitors.

promwad-mobile_zive

ZIVE radiation monitor measures gamma rays, ionizing radiation, and X-rays. Differentiating features of the device:

  • Calibrated by accredited European laboratories (CE).
  • High accuracy at a lower price in comparison with other similar devices.
  • “Smart monitor” mode that provides users with specific health and well-being advice: how to interpret the measurements and reduce the risks.
  • Working with maps to create eco-routes: save radiation spots, find cleaner routes.

The collected ZIVE data is used for the real-time global map of radiation contamination.

Roman Pakholkov, Promwad’s CEO and R-NOX’s mentor, says that the data collected by ZIVE users is stored in the eco-platform, which is becoming the most detailed in the world. This platform allows accelerating the innovations development for the environmental management and can be integrated into other devices and applications via the open API.

To date, R-NOX has developed partnerships with the largest tour operator in the Chernobyl Nuclear Power Plant Zone of Alienation; Greenpeace; companies and organizations in Japan, Finland, Singapore, and other countries.

Promwad continues its work in supporting new electronics design projects in the IoT field. The company believes in the high potential of this popular trend and are ready to share their experience in the development and manufacture of electronic products for the global consumer electronics market.

The best companies of Elektra Awards 2016 will be announced on Thursday, 1st December, at the awards ceremony taking place in The Ballroom, Grosvenor House Hotel, London.

Contact-Details:
promwad-logo
Promwad

Olga Potonya
olga.potonya@promwad.com
+370 (5) 214 12 44 ex.227

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Drugs, Health 2.0, Healthcare Products, Healthcare Professionals, Healthcare Services, Healthcare Software, Healthcare Solutions, Pharmaceuticals

Global leader in serialization solutions Systech to attend the annual pharmaceutical congress CPhI Worldwide in Barcelona, 4 – 6 Oct 2016

Leave a comment

systech_international_slogo_europawireBRUSSELS, 28-Sep-2016 — /EuropaWire/ — Systech International, a global leader in brand protection technologies, will partner with Sharp Packaging and SINEL SYSTEMS, part of the Autajon Group, at CPhI Worldwide, the annual pharmaceutical congress held in Barcelona from 4 – 6 October 2016.

Systech will be part of Sharp’s panel discussion addressing delegates on the theme of “Serialization: Optimizing Your Supply Chain Means Optimizing Your Partners.” The presentation will explore the critical path to supply chain readiness, risk assessment, benchmarking and serialization risk mitigation options. The briefing will take place in the Pharma Insight Briefing room on Tuesday, 4 October 2016 at 11:30am CEST.

Systech will also showcase its UniSeries™ serialization software offered as an integrated solution within Autajon’s exhibit booth #2P16 (Hall 2).

CPhI Worldwide, together with co-located events ICSE, InnoPack, P-MEC and FDF, will host more than 36,000 visiting pharma professionals from 4-6 October at the Fira Gran Via, Barcelona, Spain. More than 2,500 exhibitors from 150+ countries gather at the event to network and take advantage of more than 100 free industry seminars. Every sector of the pharmaceutical market is represented under one roof, this year in a new location in Barcelona.

With thousands of implementations across the globe, Systech is the world’s most trusted brand protection expert, and its UniSeries offering is the industry standard for serializing products. UniSeries is offered as an integrated solution with both Sharp Packaging and Autajon Group’s hardware. Systech’s patented, configurable software offers manufacturers the flexibility to adapt to new regulations without extensive reworking or revalidation, thereby reducing implementation, training and support costs.

“We are recognized as the world leader in serialization and brand protection,” states Manfred Voglmaier, Senior Director Sales Europe, Systech International. “With more than 30 years of experience in providing highly configurable solutions for serialization across a variety of industries ― along with our partners Sharp Packaging and Sinel ― gives us a unique insight for this panel.”

Systech’s products are in greater demand than ever before since it is estimated that over 15,000 production lines for prescription medication in Europe must be fitted with a serialization system over the next three years. The European Commission adopted a regulation on October 2, 2015, under which the serialization of prescription medicine packages will become mandatory in all EU countries by 2019.

Show exhibit hours are on Tuesday, 4 October – Thursday, 6 October. Systech representatives will be available in the Sharp Packaging booth #3L56 (Hall 3) during the event, as well as in the Autajon booth #2P16 (Hall 2). They will showcase Systech’s software solutions on sample packaging lines and via live demos throughout the event.

SOURCE: EuropaWire

Business of Medicine, Consultations, Drugs, Healthcare Software, Healthcare Solutions

Finnish Servicepoint to resell, install and support Systech’s serialization solutions in Scandinavia, the Baltic States, and Russia

Leave a comment

servicepoint-fi__logo_europawireFinland, 23-Sep-2016 — /EPR HEALTHCARE NEWS/ — Systech International, a global leader in brand protection technologies, today announces the extension of its strategic partnership with Servicepoint, a leading serialization automation supplier.

Systech has signed a global agreement with Servicepoint, allowing the company to act as a single point of contact for customers across Europe. Through this agreement, Servicepoint will now resell, install and support Systech’s serialization solutions to customers of any size across Europe, especially in Scandinavia, the Baltic States, and Russia.

This agreement comes at a critical time within the pharmaceutical industry, as the European market is growing exponentially. It is estimated that over the next three years, 15,000 production lines for prescription medication in Europe must be fitted with a serialization system. The European Commission adopted a regulation on October 2, 2015, under which the serialization of prescription medicine packages will become mandatory in all EU countries by 2019.

Systech and Servicepoint first engaged two years ago when jointly delivering serialization and automation/integration solutions to a pharmaceutical manufacturing client. As a result, both companies were able to offer enhanced solutions and increase their speed of delivery.

Servicepoint maintains and offers professional services, automation services, retrofit/upgrade services to Systech customers and provides Level 1 and 2 support, while Systech provides Level 3 support for the software.

“Servicepoint has a solid network of over 50 professionals in Europe, which, when combined with Systech’s growing regional support, creates a large and experienced talent pool for the delivery of serialization initiatives,” states Harry Saint-Preux, Director, Global Alliances & Channels, Systech International.

“Servicepoint has extensive expertise and a long history automating hundreds of production lines for different fields of industry and European pharmaceutical manufacturers, as well as experience with track-and-trace initiatives. Systech and Servicepoint’s combined approach provides manufacturers with the solutions, services and support required to address Europe’s challenging serialization requirements,” notes Saint-Preux.

Risto Finne, chairman of the board, Servicepoint, comments, “Servicepoint is honored to enter into this partner agreement with Systech, who we consider to be the global market leader in serialization. This cooperative paves the way for numerous new business opportunities, particularly with Russian companies that need to rapidly employ serialization. Our experience in integrating modifications and upgrades of existing production lines, in addition to new, turnkey, fully-automated solutions for the serialization and packing of medical, food and other sensitive products puts us in an enviable market position.”

Servicepoint is one of only a handful of suppliers in the European market that provides an all-inclusive production automation solution including planning, installation, testing, and maintenance.

SOURCE: EuropaWire

Biotech, Child health, Diagnostics, Health 2.0, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Services, Healthcare Software, Healthcare Solutions, Medicine, Online, Physicians, Sports Medicine, Therapies

Sway Medical’s app for sports concussion exam received European CE Mark as Medical Device

Leave a comment

sway-concussiontest-is-a-validated-ios-app-based-concussion-management-system

TULSA, OK, 08-Sep-2016 — /EPR HEALTHCARE NEWS/ — Sway Medical is a US medical device company who’s software turns an iPhone or iPad into a mobile medical device that provides immediate medical grade, objective concussion measurement to medical professionals.

Sway Medical LLC (Sway) would like to announce its official availability in all European Union Countries. Sway was issued its CE Mark after being marketed in the United States and Canada for two years. This is significant because European sports organizations ranging from youth through pro level now have an affordable and convenient sideline assessment tool supporting concussion related medical decision making. Medical professionals and trained coaches can obtain a concussion assessment via an Apple mobile device (iPhone or iPad) and the Sway Balanceâ„¢ System web-portal. Acute objective measurements are obtained by performing a 1.5 minute balance and reaction time test protocol. Licensed athletic trainers, physical therapists and athletic therapists are able to join physicians in acutely managing the underserved market of youth sports, ages six and older.

Concussion injuries are very common in sports, often going un-reported or ignored until the obvious symptoms have incapacitated the athlete or draws the attention of a parent or coach. Second Impact Syndrome (SIS) is a serious medical condition with published mortality rates of up to 50%. SIS occurs when an athlete returns to play while still recovering from an initial concussion injury. During this time, the brain is highly susceptible to additional injury and complications. The Sway Balance™ System is able to accurately assess and track the acute and chronic outcome related to an athlete’s balance, motion reaction time and concussion symptoms. The Sway Balance™ System provides a graphical representation comparing suspicious injury event tests against a pre-injury “normative” or baseline score. The comparison of event tests against an established baseline is a common measurement for traumatic brain injury diagnosis and recovery tracking.

The Sway Balance™ System is available for purchase by licensed medical professionals involved in school, occupational or sports medicine through www.swaymedical.com. Additional protocols are available to assess an individual’s “Fall Risk” or “Functional Status”.

SOURCE: EuropaWire

Biotech, Diseases, Genetics, Healthcare, Healthcare Services, Healthcare Solutions, Pharmaceuticals

GenQual and R-Pharm collaborate to deliver predictive diagnostics for novel anti-IL-6 antibody for autoimmune diseases

Leave a comment

Seattle, WA, San Francisco, CA and Moscow, Russia, 2016-May-25 — /EPR Healthcare News/ — R-Pharm and GenQual are pleased to announce a new collaboration focused on the development of novel predictive diagnostic tools in the area of Rheumatoid Arthritis and Autoimmune diseases.

The GenQual proprietary real-time PCR platform, when applied to the genes that are involved in the manifestation of several autoimmune diseases, allows us to detect and assess single nucleotide polymorphisms. Here, allelic determination is used as potential predictor of the treatment response by the novel anti-IL6 antibody, which is currently in development by R-Pharm.

GenQual Founder and CEO Jonathan Mirich said, “This partnership is exciting for GenQual as we advance in our goal to deliver predictive diagnostic tools for the treatment of autoimmune disorders. We are very excited about the possibilities in this space and are thankful to have quality partners in R-Pharm.”

R-Pharm CEO Vasily Ignatiev indicated the importance of the Autoimmune diseases as an area of the development and growth for R-Pharm, as well as the development of novel diagnostic tools aimed to increase the level of predictive response and efficiency of the upcoming treatment paradigm.

About GenQual
GenQual develops proprietary biomarker diagnostics for autoimmune and oncology indications.  Our personalized medicine products are designed to facilitate early disease detection and diagnosis, and to improve treatment approaches at the molecular level.  GenQual is a privately-held corporation based in Seattle, WA area, USA.

About R-Pharm
R-Pharm is a private Russian pharmaceutical company founded in 2001. It employs over 3,500 highly qualified specialists in 60+ branches. R-Pharm operates in Russia and CIS, USA, Germany, Japan, Turkey/MENA.

The company is involved in R&D, manufacturing (finished dosage forms, biotech and chemical APIs), marketing, sales and distribution of innovative pharmaceutical products in hospital/specialty care therapeutic areas.

R-Pharm collaborates with major international pharmaceutical companies and universities in the fields of drug discovery, development, clinical trials, manufacturing and commercialization.  The company operates several  GMP compliant manufacturing sites in Russia and Germany, research, BD/licensing and marketing affiliates in Japan, Germany, Turkey and US.

Marketed portfolio and pipeline features drugs used in oncology, hematology, autoimmune diseases, HIV, HCV, neurology, diabetes, cardiology, as well as antibiotics, contrast media and anesthesia agents.

Contact

R-Pharm
info@rpharm.ru
www.r-pharm.com/en/

 

GenQual

info@genqual.com
206.659.7825
www.genqual.com

 

Via EPR Network
More Healthcare press releases

Health Products, Healthcare, Healthcare Products, Healthcare Services, Healthcare Solutions

HTN propone EASY BLOOD PRESSURE, una nuova e facile soluzione per il monitoraggio domiciliare della #pressionearteriosa

Leave a comment

Brescia, Italia, May 19, 2015 — /EPR NETWORK/ — Secondo la #SIIA (Società Italiana dell’Ipertensione Arteriosa), in Italia


• il 31% delle donne ed il 33% degli uomini soffre d’ipertensione arteriosa*
• il 14% delle donne ed il 19% degli uomini “sani” sono in una condizione di rischio**
• solo il 35% degli ipertesi trattati ha valori di pressione arteriosa normalizzati”***
• l’obbiettivo è portare, entro il 2015, il 70% della popolazione degli ipertesi alla normalizzazione dei valori di pressione arteriosa.

* Ipertesi: sono i pazienti con pressione arteriosa uguale o superiore a 140/90 mmHg..
** Condizione di rischio: quando il valore della pressione sistolica è compreso fra 140 e 160 mmHg e quello della diastolica è compreso fra 90 e 95 mmHg.
*** Secondo le Linee Guida Europee 2013 i valori di norma sono quelli inferiori a 130/85..

Le Linee Guida 2013 della Società Europea dell’#Ipertensione sottolineano che i valori di pressione arteriosa rilevati al domicilio hanno un significato prognostico maggiormente predittivo di accidenti cardiovascolari rispetto ai valori rilevati in ambulatorio.
#HTN Easy Blood Pressure è l’abbonamento annuale per il monitoraggio della pressione arteriosa, in modo semplice ed efficace.

Il servizio si basa sull’utilizzo, in alternativa, di due device per la rilevazione dei valori della pressione arteriosa:
• iHealth BP5, a trasmissione via Bluetooth
• A&D UA-767NFC, a trasmissione via NFC
L’abbonato è in grado di rilevare quante misure desidera e tutte saranno trasmesse, attraverso uno smartphone, al proprio Personal Health Record, sempre accessibile in modo sicuro, attraverso la piattaforma software proprietaria #SmartTelemedicine.
Ogni tre mesi, oppure a sua richiesta, riceverà un referto sui valori registrati.

In sintesi, l’offerta prevede:
• quattro prestazioni di refertazione specialistica dei valori pressori all’anno
• una chiamata a personale sanitario HTN all’anno
• fino a 4 Personal Health Record sulla piattaforma software SmartTelemedicine
• il comodato d’uso gratuito dell’apparecchiatura #iHealth BP5 ovvero A&D UA-767NFC
Ulteriori prestazioni di refertazione e/o teleconsulto possono essere richieste in qualsiasi momento.

Per maggiori informazioni: http://www.e-htn.it/it/contatti/

Contact-Details: Dr. Fulvio Glisenti – Presidente, Health Telematic Network s.r.l.
info@e-htn.it

Via EPR Network
More Healthcare press releases

Biotech, Healthcare, Healthcare Solutions, Public Health, Society, Therapies

Regenexx Announces the Publication of “Orthopedics 2.0 – How Regenerative Medicine and Interventional Orthopedics will Change Everything” on Amazon Kindle

Leave a comment

Broomfield, CO, February 02, 2015 — /EPR HEALTHCARE NEWS/ — With more than 40,000 downloads, “Orthopedics 2.0 – How Regenerative Medicine and Interventional Orthopedics will Change Everything” is now available on Amazon Kindle. The third edition of the top-selling e-book is being offered as a free download through Jan. 6, 2015.

Written by Dr. Chris Centeno, this e-book delves into the human musculoskeletal system and explains how everything works together in concert to maintain our physical wellbeing. When a single component in this chain is damaged, it can lead to a cascade of joint, spine and connective tissue problems, resulting in chronic pain.

Using the Regenexx SANS approach, Orthopedics 2.0 walks you through a series of tests and exercises that you can do on your own to better understand where your own body is struggling to maintain proper stability and alignment, explaining the possible reasons and long term implications along the way. Orthopedics 2.0 also explores how Regenexx is pioneering the new field of Interventional Orthopedics, where the use of regenerative biologic treatments, such as adult stem cell therapy and platelet rich plasma, are being used to help repair and strengthen damaged tissues, as opposed to invasive surgeries that often remove important tissues when a joint or the spine becomes damaged.

With hyperlinks to more detailed information, related studies and commentary, this book condenses a vast amount of data and resources into an enjoyable and entertaining read.

About Regenexx
Since its genesis in 2005, Regenexx has been a world-leader in the use of adult stem cell treatments for orthopedic conditions, providing non-surgical, biologic therapies delivered with high accuracy through a needle. Regenexx has collected and published more data on stem cell patients than any other company and are dedicated to reinventing orthopedic care to help patients avoid invasive surgery.

Featured on television and media outlets such as the Doctors TV show, ABC News, Good Morning America and many others, Regenexx is taking orthopedic stem cell therapy to an exciting new level.

For more information about this e-book or to talk with a Regenexx Liaison, please call 888-525-3005 or email info@regenexx.com. Visit Regenexx online at:http://www.regenexx.com/

Contact-Details: Regenexx
Contact: Mark Testa
403 Summit Blvd., Suite 201
Broomfield, CO 80021
Phone: 888.525.3005
Email: info@regenexx.com
Web – http://www.regenexx.com/

Via EPR Network
More Healthcare press releases

Biotech, Drugs, Healthcare Products, Healthcare Services, Healthcare Solutions, Medicine, Society

ViroCarb’s anti HIV Crowd Funding Campaign

Leave a comment

Toronto, Canada, December 01, 2014 — /EPR HEALTHCARE NEWS/ — ViroCarb Inc. has launched a worldwide crowd funding campaign to promote the development of its new HIV infection inhibitor.

WORLD AIDS DAY – Make a donation to save lives from AIDS! Support new treatment development at: https://www.indiegogo.com/projects/funding-a-new-therapy-against-drug-resistant-hiv/x/9240077

Despite the great progress made in HIV/AIDS treatment, there is still an urgent need for new drugs, particularly for people who have had to abandon existing treatments due to HIV drug resistance and side effects.

The current treatment of HIV/AIDS involves the use of three or more drugs from five main general classes, used in combination. While this antiretroviral therapy (ART) has helped to reduced morbidity and mortality from AIDS, long term toxicity and the emergence and transmission of drug resistant HIV strains limit the effectiveness. Thus, despite therapy which can render this a chronic, rather than acute fatal infection, development of new drugs to prevent infection and overcome drug resistant strains, is increasingly urgent.

ViroCarb Inc. is developing a novel technology that addresses infections by drug resistant HIV strains. Developed from the identification of a new, natural resistance factor against HIV infection by scientists at SickKids and Canadian Blood Services, ViroCarb’s inhibitor works against a previously overlooked target on the virus to block HIV from entering human cells, the very first step in the infection. It works against all HIV strains.

Funds are needed to aid in moving forward to support preclinical studies; therefore ViroCarb Inc. has started an international crown funding campaign to carry out these HIV model studies needed before conducting clinical trials.
Please support this new way to block HIV.

Contact-Details: Dr. Mario Huesca
479 Simonston Boulevard.
Thornhill ON.
L3T 4M4 Canada

Facebook: https://www.facebook.com/ViroCarb;
Website: http://www.virocarb.com

 

Via EPR Network
More Healthcare press releases

Donation, Healthcare, Healthcare Products, Healthcare Solutions, Public Health

Hays PureWater Launches $10,000 Campaign To Save Lives

Leave a comment

WASHINGTON, IA, November 25, 2014 — /EPR HEALTHCARE NEWS/ — 783 million people live each day without clean water and 3.4 million die annually from a lack of pure water. To combat these staggering statistics, Washington-based nonprofit, Hays PureWater, launched a crowd-funding campaign. The money raised will fund 30 Khlor Glen technology units to purify water for 150,000 individuals. The organization hopes to raise $10,000 by December 1st.

Hosted on crowd-funding platform IndieGoGo, the project offers nine sponsorship levels. Each level includes novelty “rewards” for donors, ranging from stickers to t-shirts to a trip to Haiti. The rewards are unique, innovative and hands on, giving donors a sense of ownership in the project. For just $2,500, an investor can travel to Haiti (all inclusive) to see the life changing benefits first hand.

The Khlor Glen is a simple unit that turns salt water into chlorine. The chlorine treats infected water, removing deadly impurities and toxins in just one hour. It’s solar powered and easily used in remote areas, where clean water is most needed. “It will also impact malaria zones as it can be used as a bug repellant and protect from disease,” says founder John Hays. “Even just using the chlorine produced by the unit as a sanitizer can cut down on so many infections that the natives in these areas don’t even know exist.”

In the last eight years, Hays PureWater distributed over 4,000 purifying units around the world, changing entire communities by implementing this system. It’s proven to work. Hays builds each system with the help of a dedicated group of volunteers. Nothing is outsourced, ensuring the most effective product for the lowest cost. Now all they need is help from their community to change the lives of those in need once more.

See the crowd-funding campaign here: https://www.indiegogo.com/projects/hays-purewater-providing-clean-water-globally

ABOUT Hays PureWater
In 2006, after traveling around developing nations on missions trips, John Hays began to create a low cost, portable solution for water purification. John, who worked with municipal water works for over 30 years, put his experience to use and developed the Khlor Gen system. Through the years, the design and look has been changed and improved, but the mission has stayed the same. The organization exists to provide people with clean water, reaching out to them through word and deed. Eight years and 4,000 units later, that mission continues full steam ahead. For more information, logon to www.hayspurewater.com.

###

Contact-Details: TJ Widbin
tj@hayspurewater.com
319-470-7391

Via EPR Network
More Healthcare press releases

Assistants, Business of Medicine, Clinics, Doctors, Health 2.0, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Services, Healthcare Software, Healthcare Solutions, Hospitals, Medicine, Online

Health Gorilla Releases Mobile Application for Doctors

Leave a comment

Digital Health Leader Expands Marketplace Access with Mobility

SUNNYVALE, CA., 2014-8-20 — /EPR Healthcare News/ — Health Gorilla™, Inc., the first online healthcare marketplace to connect doctors and clinicians with over 9,000+ diagnostic labs and 35,000+ radiology centers, has announced today the release of Health Gorilla mobile.  Health Gorilla mobile provides access to the Health Gorilla Marketplace through the Apple® iPhone® and iPad™.

Today over 68% of doctors have standardized on the Apple platform to communicate with peers and patients. Doctors can now use their mobile devices to place electronic orders with Health Gorilla mobile to diagnostic labs, radiology centers, physical therapy, skilled nursing facilities (SNFs) and durable medical equipment (DME) and other medical providers nationwide with the ability to track and review the results instantly as they arrive.  Physicians can then forward electronic results within their practice or exchange them with peers and patients to streamline the process and improve quality of care.

According to a study published by the New England Journal of Medicine noted that approximately 59.3% of all of a primary care physician’s daily emails were for the interpretation of test results and 21.7% were responses to patients.  The use of email generally increases the risk for doctors and their patients as most email services are not HIPAA compliant.

Another study published in the Journal of the American Medical Association (JAMA) reported that researchers from the Michael E. DeBakey Veterans Affairs Medical Center in Houston conducted a survey of primary care practitioners and found that a third reported missing alerts about test results from an electronic health record notification system designed to inform them when a patient has abnormal test results.

Doctors are adopting iPad and iPhones as the platform of choice to communicate with peers and patients. Health Gorilla mobile integrated messaging greatly reduces the risk in communication between a doctor and their patients by offering a fully HIPAA compliant environment. Health Gorilla mobile enables a physician to securely and compliantly forward diagnostic test results, radiology images, admission and discharge summaries and other clinical documents to patients and care coordinators through secure messaging.

Benefits of Health Gorilla Mobile Include:

  • HIPAA compliant and ONC modular certified MU2 solution
  • Order in less time than it takes to use fax forms
  • Receive results faster wherever you are
  • Forward results to patients instantly
  • Immediately refer results to another doctor and send messages
  • Eliminate error prone paper processes
  • Mobile solution available at no charge for doctors and their teams

“We believe that the value proposition is clear and compelling for doctors and their teams.” said Steve Yaskin, Chief Executive Office, Health Gorilla, Inc.  “The existing process is heavily dependent on paper, fax and manual processing.  It is slow, cumbersome and prone to error.  Doctors can better manage their time, and the time of their administrative and care coordinating teams, by using the power of the marketplace through the Health Gorilla app.  Now they have one place to order from any diagnostic lab, radiology center, hospital, physical therapy, sleep center, SNF and other healthcare providers in the United States.  A doctor can start with us the first day and begin ordering through the marketplace immediately.  Health Gorilla is the first to deliver this capability.  No other vendor can provide this benefit.”

Health Gorilla mobile is available as an approved Apple® enterprise application and will be distributed to existing Health Gorilla Marketplace users via a secure link for the next month.  In September Health Gorilla mobile app will be available from the Apple® store and will be fully integrated with the Apple® Health app upon its release.

About Health Gorilla
Health Gorilla™ is the first online healthcare marketplace to connect all doctors and clinicians with over 9,000+ diagnostic labs and 35,000+ radiology centers.  Doctors and their teams can instantly place orders, get results, and completely eliminate paper faxes. Uniquely, our HIPAA compliant and ONC modular certified MU2 solution is available immediately at absolutely no charge for doctors and clinicians.

Watch our 2 minute video Intro to Health Gorilla: http://youtu.be/6Luo5eNG8-s
Tweet: https://www.twitter.com/healthgorilla
Facebook: https://www.facebook.com/healthgorilla
LinkedIn: https://www.linkedin.com/company/2542523?
Sign-up for our Newsletter at the bottom of homepage:
http://www.healthgorilla.com

Contacts

For additional information contact Joe Austin via jaustin@theventanagroup.com or call 818-332-6166.

Health Gorillaâ„¢ is a trademark of Health Gorilla, Inc.
Apple®, iPhone®, iPad mini™ are trademarks of Apple, Inc.

Health Gorilla Releases Mobile Application for Doctors
Health Gorilla Releases Mobile Application for Doctors
Health Products, Healthcare, Healthcare Solutions, Society

Freya – The New Efficient App For Women Is On Kickstarter

Leave a comment

The HedgeHog team is proud to present yet another app solution – a circular ovulation calendar that is both simple, efficient and aesthetic. Based on the popular calendar CircleTime, Freya tells you when is the best time to try to conceive or to use protection. It can also be used during pregnancy for counting the remaining time before the estimated due date.

The app, named after the Scandinavian goddess of love, sexuality, beauty and fertility – Freya offers a simple solution – without the countless irrelevant information you’ll never require. Freya’s mission is to be clear and effective.

We invite all who wish to see this app released as soon as possible, to assist the HedgeHog team with achieving their funding goal on the crowdfunding site Kickstarter. Participants have a unique opportunity to receive some genuine rewards made of natural and environmentally friendly materials. This is because sustainable development is one of the top priorities for the team and they wish to see all the natural beauty restored to the environment.

“The purpose of Freya is to provide a remarkable menstrual calendar for women which will be immensely appealing in both appearance as well as functionality”, said Sabina Durini, Freya designer and member of the HedgeHog team.

The fundraising campaign will last for 30 days and the app will initially be developed for Apple iOS devices.

Project page: https://www.kickstarter.com/projects/hedgehog-si/freya-ovulation-calendar-simple-solution-for-every
Official website: http://www.newroundcalendar.com/freya.html

Contact Details: Daniel Nunic
App Developer
Email: daniel@hedgehog.si
Phone: +38640667308

MEDIA:

PHOTO:

JPEG

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Healthcare, Healthcare Products, Healthcare Solutions, Medicine, Pharmaceuticals

HD Biosciences, Co., Ltd. and E. J. Corey Institute of Biomedical Research Reached Agreement for Drug R&D Collaboration

Leave a comment

HD Biosciences Co., Ltd. (HDB) and E. J. Corey Institute of Biomedical Research (CIBR) announced that they have reached a risk-sharing agreement on collaborative drug discovery and development in the therapeutic areas of infectious diseases, metabolic diseases, and oncology. This joint effort will focus on both international and Chinese markets to provide innovative medicines for unmet healthcare needs. The agreement includes lead candidate selection pre-clinical development, IND filing, clinical trials, and NDA approvals. Both companies will share financial returns from any successes or products launches.

“We are delighted to enter this partnership. The collaboration will leverage HDB’s extensive capabilities in preclinical drug discovery and development, and create long term potentials for the company.” stated Xuehai Tan, Ph.D., President & CEO of HDB. “In combination of CIBR’s expertise in drug development, we are confident to deliver novel drug candidates over the next few years, and to make this partnership a success.”

“Working with HDB gives CIBR a unique opportunity to showcase its strength in innovative drug discovery and development,” said Wuyi Meng, Ph.D., President of CIBR. “This partnership further demonstrates CIBR’s commitment in the betterment of patient’s lives by bringing forward novel medicines. We will collaborate closely with HDB to accelerate the progress of our collaborative programs”

About HD Biosciences Co., Ltd.
HD Biosciences Co., Ltd. is a Shanghai-based, biology-focused preclinical drug discovery contract research organization (CRO). The company offers comprehensive service platforms around target validation, plate-based pharmacology, hit identification and lead discovery, therapeutic antibody discovery, in vivo pharmacology, as well as other research and development services. The company currently collaborates with eight of the ten largest pharmaceutical companies in the world and has established strategic partnerships on many key R&D areas with impacts to their portfolios. The strong scientific expertise, high quality and consistency in deliveries, constantly meeting or exceeding expectations, has earned the company a great reputation in the industry, and helped the company to build its widely recognized leadership in preclinical contract research services.http://www.hdbiosciences.com

About E. J. Corey Institute of Biomedical Research
Located in the Jiangyin High-tech Industry Development Zone in Jiangyin, Jiangsu, E. J. Corey Institute of Biomedical Research (CIBR) is a non-profit research organization founded by Nobel laureate Prof. E. J. Corey with the support from Jiangyin and Jiangsu government. CIBR is committed to scientific research in the broad biomedical field and to the development of novel therapeutics to meet the unmet medical needs of patients. In addition to its strong internal research and discovery capabilities in biomedical research and drug discovery, CIBR has established solid external capabilities in translational medicine and molecular toxicology to support drug development. Under the guidance of Nobel laureate Prof. Corey, CIBR is well poised to contribute to the discovery and development of novel medicines. http://www.cibrnobel.org

Contact Details:
HD Biosciences
Ms. Jessie Yang
Email: yangxiaojie@hdbiosciences.com

CIBR
Dr. Jiaquan Wu;
Email: jwu@cibrnobel.org

 

Via EPR Network
More Healthcare press releases

Alternative medicine, Healthcare, Healthcare Information, Healthcare Solutions, Homeopathic Treatment, Public Health, Society

Leaky Gut Cure Through Holistic Nutrition Announced

Leave a comment

Sufferers of leaky gut syndrome will be cheered by Karen Brimeyer’s announcement of a program called “Leaky Gut Cure” that can relieve symptoms and ease suffering from the crippling digestive track disorder. Based on healthy lifestyle recommendations, this holistic cure is based on dozens of effective ideas evolved over stringent testing and experimentation.

Nearly 2 million people have leaky gut syndrome, a poorly defined and often under-diagnosed gastro-intestinal system disorder that causes belly aches, bowel disturbance and food sensitivities. Patients often complain of abdominal cramps, bloating, flatulence and indigestion. Tired of one fad diet after another, people who have silently suffered from the condition will find this leaky gut syndrome cure the answer to a prayer.

“Obviously this system is based on extensive testing, and the author has clearly tried these methods out herself before suggesting it to others,” opined one of the early reviewers who thought the 5-point program was likely to help her. Many others who have undergone the holistic program have echoed similar sentiments.

The system called “Leaky Gut Cure” was devised by Karen Brimeyer who is a holistic nutritionist and functional medicine practitioner. It is based on a five part sequence of advice that has been shown to reverse or at least mitigate leaky gut syndrome with all her own clients. The newly packaged course takes this information out to a new audience across the world.

“The health of your gut is important in your overall health and well being” says Karen. “Leaky Gut Cure is powerful information for anyone who could be having undetected gastrointestinal disorders resembling the syndrome.”

Many effective treatments and lifestyle changes are revealed in this guide, including 3 health foods that are widely recommended and consumed by millions of people daily, but that could make the symptoms of leaky gut syndrome worse. Considering how beneficial it is to sufferers, the program is affordable and widely accessible. Victims of leaky gut can get the information without wasting hundreds, or even thousands of dollars on expensive doctor visits or costly tests to detect and monitor disease progress.

Karen Brimeyer is giving away a free report that shares three effective techniques for leaky gut cure from her website. For more information about the Leaky Gut Cure go to http://www.LeakyGutCureReview.org

Contact Details: LeakyGutCureReview.org
Optibiz Publishing, P.O.Box 90012,
Chennai, TN 600107
info@LeakyGutCureReview.org
http://www.LeakyGutCureReview.org

Via EPR Network
More Healthcare press releases